Steven J. Moore

Head of US intellectual property | San Diego New YorkGreenwich

Secretary Joyce Davis


Track record

Patent practice regulations

Steve is probably best known for acting as lead counsel in the representation of Dr Tafas in the suit of Tafas v. Dudas, in which a successful challenge was brought against certain regulations to change continuation and claim practice in the United States. The regulations were understood through the patent field to have widespread effects on patent practice, and to increase costs substantially for the maintenance of patent portfolios. For his actions in the case, he was awarded the Case of the Year (2009) by a number of organizations including Managing Intellectual Property. His client, Dr Tafas, won the prestigious Jefferson Medal by the New Jersey Intellectual Property Association, becoming one of the few non-lawyers to ever receive the award.


  • 'Key Patent and IP Issues in M&A Transactions', Continuing Legal Education course to members of Association of the Corporate Counsel-San Diego chapter, San Diego, CA, February 18, 2016

  • 'Of Prior Art and Double Patenting: Exploring the Dichotomy Between the Federal Circuit and PTO on Obvious Findings and the Potential Impact of the Goodlatte Bill on Double-Patenting Type Obviousness', ACI's Eighth Annual Paragraph IV Disputes, New York, April 2014

  • 'Patent Law for Non-Patent Lawyers', New York City Bar, New York, December 2013

  • 'Non-Practicing Entities,' CTIC Patent Reform Conference Patent Reform: Theoretical Propositions and Factual Foundations, __ University of Pennsylvania Law School, Philadelphia, December 2013.

  • 'Examining New Rulings in Inducement of Infringement and Divided Infringement and Their Application to Method Claims in Hatch-Waxman Litigation', ACI's Seventh Annual Paragraph IV Disputes, New York, May 2013

  • 'The New Reexamination Procedures in the United States', Intellectual Property Rights Conference, Bangalore, India, January 2013

  • 'Inequitable Conduct Post-Therasense and How It Impacts Life Cycle Planning', 13th Annual Maximizing Pharmaceutical Patent Life Cycles Event, New York, October 2012

  • 'Patent v. Antitrust Law in the 21st Century', New York City Bar, New York, June 2012

  • 'New Standards in Inequitable Conduct Post-Therasense: Ethical Considerations for Paragraph IV Cases', ACI's Sixth Annual Paragraph IV Disputes, New York, April 2012

  • 'Damages and Injunctions: Exploring the Consequences and Conundrums of Launching at Risk', ACI's Fifth Anniversary Edition Paragraph IV Disputes, New York, May 2011

  • 'Factoring Recent Local Patent Rule Changes, Jurisdictional Considerations and Patent Reform Legislation into Your Litigation Strategy', ACI's Third Annual Paragraph IV Disputes, New York, April 2009

  • 'Constructing, Adjusting, and Executing a Pharmaceutical Patent Life Cycle Management Plan', 9th Annual Maximizing Pharmaceutical Patent Life Cycles Conference, New York, October 2008

  • 'KSR and Obviousness', 8th Annual Maximizing Pharmaceutical Patent Life Cycles conference, New York, October 2007

  • 'How to Align Your Pharma Patent Portfolio with Recent Supreme Court decisions and the New USPTO Regulations', The Center for Business Intelligence webinar series, New York, October 2007

  • 'Expert Insights on Hatch-Waxman Litigation Strategies for Brand Names and Generics', ACI Paragraph IV Disputes, April 2007